Results 1 to 10 of about 4,524 (132)

Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms

Cancer Medicine, 2020
Treatment with PEGylated interferon‐alpha2 (IFN) of patients with essential thrombocythemia and polycythemia vera induces major molecular remissions with a reduction in the JAK2V617F allele burden to undetectable levels in a subset of patients.
Rasmus K Pedersen, Lasse Kjær, Morten Andersen   +2 more
exaly   +2 more sources

JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages

Frontiers in Immunology, 2021
A substitution mutation of valine to phenylalanine at codon encoding position 617 of the Janus kinase 2 (JAK2) gene (JAK2V617F) has been detected in myeloid cells of some individuals with higher levels of proinflammatory cytokine production such as ...
Hirotaka Mori, Kui-Yang Zheng, Hiroshi Ohkawara   +2 more
exaly   +3 more sources

Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms

Haematologica, 2021
JAK2V617F is the most frequent driver mutation in myeloproliferative neoplasms (MPNs) and is associated with vascular complications. However, the impact of hematopoietic JAK2V617F on the aortic aneurysms (AAs) remains unknown.
Tetsuro Yokokawa, Tomofumi Misaka, Yusuke Kimishima, Kento Wada, Keiji Minakawa, Koichi Sugimoto, Takafumi Ishida, Soji Morishita, Norio Komatsu, Kazuhiko Ikeda, Yasuchika Takeishi   +10 more
doaj   +1 more source

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm

Blood Cancer Journal, 2023
SRSF2 mutations are found in association with JAK2V617F in myeloproliferative neoplasms (MPN), most frequently in myelofibrosis (MF). However, the contribution of SRSF2 mutation in JAK2V617F-driven MPN remains elusive.
Yue Yang, Salar Abbas, Mohammad A. Sayem, Avik Dutta, Golam Mohi   +4 more
doaj   +1 more source

Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation. [PDF]

PLoS ONE, 2015
Detection of the JAK2V617F mutation is essential for diagnosing patients with classical myeloproliferative neoplasms (MPNs). However, detection of the low-frequency JAK2V617F mutation is a challenging task due to the necessity of discriminating between ...
Soji Morishita, Kochi Takahashi, Marito Araki, Yumi Hironaka, Yoshitaka Sunami, Yoko Edahiro, Miyuki Tsutsui, Akimichi Ohsaka, Satoshi Tsuneda, Norio Komatsu   +9 more
doaj   +1 more source

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles

Turkish Journal of Hematology, 2022
Objective: Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have a high propensity for thrombosis, which has been attributed to increased blood counts, endothelial cell (EC) dysfunction, and inflammation. The presence of the JAK2V617F
Hilal Hekimoğlu, Selin Fulya Toprak, Selçuk Sözer   +2 more
doaj   +1 more source

The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden

eJHaem, 2023
Alleviating symptom burden in patients with myeloproliferative neoplasms (MPNs) is imperative to achieving optimal management. Research remains to elucidate the relationship between the JAK2V617F (Janus kinase 2) mutation present in many MPN patients ...
Lai Yee Orbell, Nouf Abutheraa, Andrew S Duncombe, Mary Frances McMullin, Ruben Mesa, Charlene M McShane, Glen James, Lesley A Anderson   +7 more
doaj   +1 more source

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm

Frontiers in Oncology, 2021
The myeloproliferative neoplasms (MPNs) are characterized by an expansion of the neoplastic hematopoietic stem/progenitor cells (HSPC) and an increased risk of cardiovascular complications.
Haotian Zhang, Amar Yeware, Sandy Lee, Huichun Zhan, Huichun Zhan   +4 more
doaj   +1 more source

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms

Turkish Journal of Hematology, 2023
Objective: The impact of JAK2V617F allele burden on clinical course in Philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs) is not clear.
İpek Yonal Hindilerden, Ezgi Şahin, Fehmi Hindilerden, Aynur Dağlar Aday, Meliha Nalçacı   +4 more
doaj   +1 more source

JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients

Hematology/Oncology and Stem Cell Therapy, 2023
Background: Mutations in JAK2/STAT5 proliferation pathway genes are key in the diagnosis of myeloproliferative neoplasms (MPNBCR/ABLneg), with JAK2V617F being found in 50-97% of MPNBCR/ABLneg subtypes.
Karen L. Shires, Adriana J. Rust, Rushil Harryparsad, Justin A. Coburn, Ruth E. Gopie   +4 more
doaj   +1 more source